Volatomics for Diagnosis and Risk Stratification of MASLD : A Proof‐Of‐Concept Study
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70176 ↗At a glance
Beobachtungsstudie in Alimentary Pharmacology & Therapeutics, 2025. Written by R Sinha and 8 co-authors. Institution: Hepatology Laboratory and Centre of Liver and Digestive Diseases, Royal Infirmary of Edinburgh, The University of Edinburgh, Edinburgh, UK. Major MEDLINE topics: Electronic Nose, Fatty Liver, Volatile Organic Compounds. Cited 7 times so far (Crossref); 36 references. Funded by: Edinburgh and Lothian Health Foundation - Diabetes Clinical Research Trust.
Abstract (original language)
Background and Aims Human breath contains numerous volatile organic compounds (VOCs) produced by physiological and metabolic processes or perturbed in pathological states. Electronic nose (eNose) technology has been extensively validated as a non‐invasive diagnostic tool for respiratory disease. Using eNose‐derived exhaled breath signals, we investigated whether it could discriminate patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) from healthy volunteers and identify patients at high risk of disease progression.
Methods
In a prospective single‐centre study, exhaled breath VOCs were analysed using an eNose, in a well‐characterised cohort comprising patients with Child‐Turcotte‐Pugh class A MASLD cirrhosis ( n = 30), non‐cirrhotic MASLD ( n = 30) and healthy volunteers ( n = 30). An unbiased machine learning clustering technique was applied. Longitudinal clinical data were collected over 5 years for the patient cohort. Logistic regression and univariable analysis were performed to identify risk factors for disease progression, liver‐related outcomes, and all‐cause mortality.
Results
Principal component analysis of breath VOCs discriminated patients with MASLD from healthy volunteers with 100% sensitivity ( p < 0.001, cross‐validation verification of 96%), independent of age and gender. The eNose breath profile classified patients with MASLD into three distinct subgroups with similar baseline clinical and demographic characteristics but markedly different prognoses. During the 5‐year follow‐up period, Cluster 2 was identified as a higher‐risk subgroup for progression (42%, p = 0.03), liver‐related decompensation events (17%, p = 0.06), and all‐cause mortality (12.5%). Conclusion eNose can discriminate patients with MASLD from healthy volunteers and, using unbiased clustering analysis, identify patients with a significantly worse prognosis. These results warrant prospective validation in independent MASLD populations. Trial Registration ClinicalTrials.gov identifier: NCT02950610
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Hepatology Laboratory and Centre of Liver and Digestive Diseases, Royal Infirmary of Edinburgh, The University of Edinburgh, Edinburgh, UK.
- The Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- Statistical Consultancy, Hemel Hempstead, UK.
- Edinburgh Centre for Endocrinology and Diabetes, Royal Infirmary of Edinburgh and the University of Edinburgh, Edinburgh, UK.
- Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.
ORCID profiles: S L Gillespie, J A Fallowfield
Funding
- Edinburgh and Lothian Health Foundation - Diabetes Clinical Research Trust
Cite
APA
Sinha, R., Gillespie, S. L., Brinkman, P., Bassett, P., Lockman, K. A., Jaap, A. J., Fallowfield, J. A., Hayes, P. C., & Plevris, J. N. (2025). Volatomics for Diagnosis and Risk Stratification of MASLD : A Proof‐Of‐Concept Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70176
Vancouver
Sinha R, Gillespie SL, Brinkman P, Bassett P, Lockman KA, Jaap AJ, et al. Volatomics for Diagnosis and Risk Stratification of MASLD : A Proof‐Of‐Concept Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70176
BibTeX
@article{Sinha2025,
author = {Sinha, R and Gillespie, S L and Brinkman, P and Bassett, P and Lockman, K A and Jaap, A J and Fallowfield, J A and Hayes, P C and Plevris, J N},
title = {Volatomics for Diagnosis and Risk Stratification of MASLD : A Proof‐Of‐Concept Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70176}
}
EUVIMED